- $86.19bn
- $108.81bn
- $176.81bn
- 56
- 68
- 76
- 74
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 10.37 | ||
| PEG Ratio (f) | 0.57 | ||
| EPS Growth (f) | 22.4% | ||
| Dividend Yield (f) | 1.86% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.03 | ||
| Price to Tang. Book | 40.22 | ||
| Price to Free Cashflow | 23.89 | ||
| Price to Sales | 0.47 | ||
| EV to EBITDA | 10.3 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 7.54% | ||
| Return on Equity | 14.24% | ||
| Operating Margin | 4.93% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 121,867 | 138,639 | 156,595 | 171,340 | 176,810 | 194,651.12 | 208,841.99 | 11.14% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +7.23 | +25.31 | -2.47 | +13.44 | -6.45 | +32.86 | +14.22 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Elevance Health, Inc. is a health company. It operates as a health insurer in the United States. The Company operates through four segments: Health Benefits, CarelonRx, Carelon Services and Corporate & Other. The Health Benefits segment offers a comprehensive suite of health plans and services to its Individual, Employer Group risk-based, Employer Group fee-based, BlueCard, Medicare, Medicaid and Federal Employee Program (FEP) members. The Health Benefits segment also offers health products on a full-risk basis. The CarelonRx segment includes its pharmacy services business. CarelonRx markets and offers pharmacy services to its affiliated health plan customers, as well as to external customers outside of the health plans. The Carelon Services segment integrates physical, behavioral, pharmacy, and social services by offering an array of healthcare-related services and capabilities to internal and external customers through its Carelon Health and Carelon Insights businesses.
Directors
- Elizabeth Tallett NEC (72)
- Gail Boudreaux PRE (61)
- John Gallina CFO (61)
- Leah Stark CHO (44)
- Gloria McCarthy EVP (68)
- Jeffrey Alter EVP (58)
- Peter Haytaian EVP (51)
- Felicia Norwood EVP (61)
- Prakash Patel EVP (54)
- Blair Todt EVP (53)
- Ronald Penczek SVP (56)
- R. Kerry Clark IND (68)
- Susan DeVore IND
- Robert Dixon IND (65)
- Lewis Hay IND (65)
- Bahija Jallal IND (59)
- Antonio Neri IND (53)
- Ramiro Peru IND (65)
- Ryan Schneider IND (51)
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- July 17th, 2001
- Public Since
- October 30th, 2001
- No. of Shareholders
- 46,307
- No. of Employees
- 103,158
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
New York Stock Exchange- Shares in Issue
- 225,934,600
- Address
- 220 Virginia Avenue, INDIANAPOLIS, 46204
- Web
- https://www.elevancehealth.com/
- Phone
- +1 3174886000
- Auditors
- Ernst & Young LLP
Upcoming Events for ELV
Q3 2025 Elevance Health Inc Earnings Release
Similar to ELV
Agilon Health
New York Stock Exchange
AMERICAN WELL
New York Stock Exchange
AMN Healthcare Services
New York Stock Exchange
Ardent Health
New York Stock Exchange
Auna SA
New York Stock Exchange
FAQ
What is the Elevance Health share price?
As of Today at 20:24 UTC, shares in Elevance Health are trading at $381.49. This share price information is delayed by 15 minutes.
How has the Elevance Health share price performed this year?
Shares in Elevance Health last closed at $381.49 and the price had moved by -28.8% over the past 365 days. In terms of relative price strength the Elevance Health share price has underperformed the S&P500 Index by -37.02% over the past year.
What are the analyst and broker recommendations for Elevance Health?
The overall consensus recommendation for Elevance Health is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Elevance Health dividend yield?
The Elevance Health dividend yield is 1.73% based on the trailing twelve month period.
Does Elevance Health pay a dividend?
Last year, Elevance Health paid a total dividend of $6.60, and it currently has a trailing dividend yield of 1.73%. We do not have any data on when Elevance Health is to next pay dividends.
When does Elevance Health next pay dividends?
We do not have data on when Elevance Health is to next pay dividends. The historic dividend yield on Elevance Health shares is currently 1.73%.
How do I buy Elevance Health shares?
To buy shares in Elevance Health you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Elevance Health?
As of the previous close price of $381.49, shares in Elevance Health had a market capitalisation of $86.19bn.
Where are Elevance Health shares listed?
Here are the trading details for Elevance Health:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: ELV
What kind of share is Elevance Health?
Based on an overall assessment of its quality, value and momentum Elevance Health is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Elevance Health share price forecast for 2025?
The analyst consensus target price for shares in Elevance Health is $493.39. That is 29.33% above the last closing price of $381.49.
Analysts covering Elevance Health currently have a consensus Earnings Per Share (EPS) forecast of $34.40 for the next financial year.
Find out moreWhat is the trend in the Elevance Health share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Elevance Health. Over the past six months, its share price has underperformed the S&P500 Index by -1.62%.
As of the last closing price of $381.49, shares in Elevance Health were trading -8.58% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Elevance Health PE Ratio?
The Elevance Health PE ratio based on its reported earnings over the past 12 months is 10.37. The shares last closed at $381.49.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Elevance Health?
Elevance Health's management team is headed by:
- Elizabeth Tallett - NEC
- Gail Boudreaux - PRE
- John Gallina - CFO
- Leah Stark - CHO
- Gloria McCarthy - EVP
- Jeffrey Alter - EVP
- Peter Haytaian - EVP
- Felicia Norwood - EVP
- Prakash Patel - EVP
- Blair Todt - EVP
- Ronald Penczek - SVP
- R. Kerry Clark - IND
- Susan DeVore - IND
- Robert Dixon - IND
- Lewis Hay - IND
- Bahija Jallal - IND
- Antonio Neri - IND
- Ramiro Peru - IND
- Ryan Schneider - IND